Thyroid gland undifferentiated (anaplastic) carcinoma

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This Phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer, a rare and fast-growing cancer with no standard cure. Participants receive the drug every three weeks to see if tumors shrink or stop growing. The study …

This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinatio…

This study tests a drug called vudalimab in people with advanced anaplastic thyroid cancer or aggressive hurthle cell thyroid cancer that has spread. The drug helps the immune system attack cancer cells and may slow tumor growth. About 54 participants will receive the treatment t…

This study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help people with a rare and aggressive thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF V600E). The goal is to shrink the tumor enough s…

This phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations…

This early-phase trial tests the safety and tolerability of combining two drugs—trametinib and paclitaxel—in people with anaplastic thyroid cancer, a rare and fast-growing cancer that is difficult to treat. The study aims to see how this drug pair affects tumor growth and shrinka…

This study tests whether adding the immunotherapy drug cemiplimab to the usual combination of dabrafenib and trametinib can shrink tumors in people with a rare and aggressive form of thyroid cancer called anaplastic thyroid cancer. Participants have a specific genetic mutation (B…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…

This phase 2 study is testing a combination of two drugs, nivolumab and lenvatinib, in 51 people with anaplastic thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors. Anaplastic thyroid cancer is rare and fast-growing…

This early-stage trial is testing an experimental drug called JSI-1187, alone or with another cancer drug (dabrafenib), in people with advanced solid tumors that have certain genetic changes. The main goal is to check safety and side effects. About 71 adults with tumors that have…

This study looks at whether proteins found in urine can help doctors diagnose follicular thyroid cancer before surgery. Currently, this type of thyroid cancer can only be confirmed after removing the thyroid. Researchers will collect urine samples from 50 patients with thyroid no…